OpenAI Acquires Orchestra Bio to Strengthen Rosalind

OpenAI announces the acquisition of Orchestra Bio, a startup specializing in AI-based biotechnology software. The team and technology of Orchestra will be integrated into the Rosalind and Rosalind Workbench projects, while the financial terms of the deal remain confidential. This move aligns with the strategy of major AI labs to develop tools for the pharmaceutical industry, raising concerns among startups in the sector.

Clients for Rosalind and Announced Integration

OpenAI has already attracted companies like Moderna and Novo Nordisk with its Rosalind model, dedicated to life sciences research. The company plans to integrate the team and technology of Orchestra Bio into Rosalind and the Rosalind Workbench tool, which is designed to help researchers plan experiments and analyze results. This acquisition comes as AI labs such as OpenAI and Anthropic increasingly develop software for major sectors like pharmaceuticals. In this context, Orchestra Bio is absorbed by OpenAI rather than facing direct competition with a new product.

Deal Announced, Terms Not Disclosed

OpenAI announced on Tuesday that it is acquiring Orchestra Bio, a startup founded four years ago that specializes in AI-driven biotechnology software. Details regarding the transaction amount have not been made public. It has been reported that Orchestra Bio raised approximately $20 million in 2025, with support from investors such as Andreessen Horowitz, Atria, and 8VC.

Skills and Tools Provided by Orchestra

Orchestra Bio develops AI agents that assist biotechnology companies in managing drug discovery operations, from financial tracking to clinical trial planning. Rosalind, OpenAI's AI model, is designed for life sciences research, while Rosalind Workbench aims to support researchers in preparing experiments and analyzing results.